Harrow Announces Agreement To Acquire Dry Eye Nasal Spray TYRVAYA From Viatris For $30M Cash At Closing, Up To $70M In Sales Milestones
Share
Why It Matters
Harrow is buying a medicine that helps dry eyes from another company for $30 million right now, plus extra money if it sells really well. This shows Harrow believes in this product and is betting it can make money from it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.